These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32728402)

  • 1. Current Trends on Glomerulosclerosis Regression.
    Stoian M; Stoica V
    J Med Life; 2020; 13(2):116-118. PubMed ID: 32728402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical approach in regression of glomerulosclerosis.
    Stoian M; Radulian G; Chiţac D; Simion E; Stoica V
    Rom J Intern Med; 2007; 45(2):215-8. PubMed ID: 18333378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of angiotensin II in glomerular injury.
    Ma L; Fogo AB
    Semin Nephrol; 2001 Nov; 21(6):544-53. PubMed ID: 11709802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights into the renin-angiotensin system and hypertensive renal disease.
    Fogo AB
    Curr Hypertens Rep; 1999; 1(2):187-94. PubMed ID: 10981064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis.
    Fogo AB
    Am J Kidney Dis; 2000 Feb; 35(2):179-88. PubMed ID: 10676714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?
    Emdin M; Fatini C; Mirizzi G; Poletti R; Borrelli C; Prontera C; Latini R; Passino C; Clerico A; Vergaro G
    Clin Chim Acta; 2015 Mar; 443():85-93. PubMed ID: 25445411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives.
    Epstein M
    Intern Med; 2001 Jul; 40(7):573-83. PubMed ID: 11506295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease.
    Brewster UC; Perazella MA
    Am J Med; 2004 Feb; 116(4):263-72. PubMed ID: 14969655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
    Brown NJ; Agirbasli M; Vaughan DE
    Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease.
    Brown NJ; Vaughan DE; Fogo AB
    Semin Nephrol; 2002 Sep; 22(5):399-406. PubMed ID: 12224047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease.
    Gupta G; Dahiya R; Singh Y; Mishra A; Verma A; Gothwal SK; Aljabali AAA; Dureja H; Prasher P; Negi P; Kapoor DN; Goyal R; Tambuwala MM; Chellappan DK; Dua K
    Chem Biol Interact; 2020 Feb; 317():108975. PubMed ID: 32032593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift.
    Epstein M
    J Hypertens; 2001 May; 19(5):829-42. PubMed ID: 11393664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
    Yoshida S; Ishizawa K; Ayuzawa N; Ueda K; Takeuchi M; Kawarazaki W; Fujita T; Nagase M
    Clin Exp Nephrol; 2014 Aug; 18(4):593-9. PubMed ID: 24154707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrarenal Renin-Angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis.
    Graciano ML; Cavaglieri Rde C; Dellê H; Dominguez WV; Casarini DE; Malheiros DM; Noronha IL
    J Am Soc Nephrol; 2004 Jul; 15(7):1805-15. PubMed ID: 15213268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone in progressive renal disease.
    Hostetter TH; Rosenberg ME; Ibrahim HN; Juknevicius I
    Semin Nephrol; 2001 Nov; 21(6):573-9. PubMed ID: 11709805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the renin-angiotensin-aldosterone system in the progression of renal disease: a critical review.
    Ibrahim HN; Rosenberg ME; Hostetter TH
    Semin Nephrol; 1997 Sep; 17(5):431-40. PubMed ID: 9316211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.
    Oikawa T; Freeman M; Lo W; Vaughan DE; Fogo A
    Kidney Int; 1997 Jan; 51(1):164-72. PubMed ID: 8995730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship of plasma renin, angiotensin, and aldosterone levels to blood pressure variability and target organ damage in children with essential hypertension.
    Liu Y; Lin Y; Zhang MM; Li XH; Liu YY; Zhao J; Shi L
    BMC Cardiovasc Disord; 2020 Jun; 20(1):296. PubMed ID: 32546130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
    Luther JM; Luo P; Wang Z; Cohen SE; Kim HS; Fogo AB; Brown NJ
    Kidney Int; 2012 Sep; 82(6):643-51. PubMed ID: 22622494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.
    Remuzzi G; Perico N; Macia M; Ruggenenti P
    Kidney Int Suppl; 2005 Dec; (99):S57-65. PubMed ID: 16336578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.